Module

Strategies for Management of Hepatitis C Treatment Failure

Source: Hepatitis Annual Update 2008

Strategies for Management of Hepatitis C Treatment Failure

Co-Chair: Mark S. Sulkowski, MD

Faculty:

Karen L. Lindsay, MD, MMM

CME CREDIT INFORMATION

Release Date: 07/07/08

Expiration Date: 07/06/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss strategies for altering the use of interferon in the management of nonresponders or relapsers, including the use of high-dose interferon and alternative interferon formulations
Review recent trial data regarding the role of maintenance therapy in nonresponders or relapsers to hepatitis C virus treatment
Describe when to recommend deferral of retreatment of hepatitis C nonresponders or relapsers

Topics covered include:

Introduction
Retreatment of Nonresponders and Responder-Relapsers Treated With Interferon
Retreatment of Peginterferon/Ribavirin Nonresponders
Retreatment of Peginterferon/Ribavirin Responder-Relapsers
Maintenance Peginterferon Therapy for Virologic Nonresponders
Future Directions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.